News

Photo of group of people standing in front of the U.S. Capitol Building

MIT Advocacy in Action at the AACR’s 2025 Hill Day

Koch Institute

May 29, 2025

MIT Koch Institute postdoc Meaghan McGeary traveled to Washington, DC to advocate for increased federal funding for cancer research as part of the annual American Association for Cancer Research (AACR) Hill Day. Joining other early-career scientists in a mission to make more than 50 congressional visits in a single day, she shared her experiences with policymakers, emphasizing the importance of stable research funding.  

Filter by

Filter by Title/Description

Filter by Topic

Filter by Year

Showing 341–350 of 638 stories

Weighing Treatment Options

MIT News

October 5, 2021

The Manalis Lab’s suspended microchannel resonator platform has been adapted into a tool for predicting patient responses to specific cancer drugs. In collaboration with the laboratory of Keith Ligon at Dana-Farber Cancer Institute, researchers measured glioblastoma cells before and after treatment with the chemotherapy TMZ in order to detect tiny changes in mass which indicate treatment response. Only half of glioblastoma patients respond to TMZ, and the genetic marker for TMZ is not a reliable predictor of sensitivity for all patients. A study appearing in Cell Reports and funded in part by the MIT Center for Precision Cancer Medicine demonstrated that the method accurately predicted response to TMZ. Travera, co-founded by Manalis and Ligon, is currently testing patient samples from several cancer types with the aim of developing clinically validated lab tests.

The Case for Cancer Vaccines

MIT News

October 2, 2021

For immunotherapy to work, T cells must recognize cancerous proteins, known as neoantigens, produced by mutated cells. Research from the Jacks Lab suggests that natural competition between T cells responding to different neoantigens limits the overall ability of T cells to control tumors. The team's findings, published in Cell and discussed on the NIH Director's Blog, demonstrate that therapeutic vaccines targeting neoantigens can alleviate T cell competition and may improve patient response to immunotherapies. Read primary author Megan Burger's interview with Oncology Times here.

This work was supported in part by the Bridge Project collaboration between the Koch Institute and Dana-Farber/Harvard Cancer Center

Leading the Way for Science and Technology

MIT News

October 2, 2021

President Joe Biden has named Paula Hammond to the President’s Council of Advisors on Science and Technology. Co-chaired by MIT’s own Eric Lander and Maria Zuber, PCAST is an external advisory board providing the White House with information and policy recommendations on matters involving science, technology, education, and innovation. Hammond, a chemical engineer working in nanotechnology, brings deep expertise in solving human health and global energy challenges, as well as dedication to improving equity and representation in STEM and public health. As director Matt Vander Heiden noted in an email to the KI community, this is an incredible honor, deserving of both gratitude and congratulations. Cheers, Paula!

Cultivating a Love of Science

MIT Biology

October 1, 2021

Affection for school may not have been in Courtney JnBaptiste’s DNA growing up on a St. Lucia farm, but this KI alum found his MIT home studying microRNAs in Phil Sharp’s lab—first as a high school student and then as a graduate student. Today, he is a patent agent, helping to transform laboratory discoveries into therapeutic practices. 

The Ins and Outs of Metastasis

MIT News

September 29, 2021

The Manalis Lab, in collaboration with the Jacks Lab, uses a novel cell-counting device to measure the frequency at which tumors shed circulating tumor cells into the bloodstream and how long these CTCs remain in circulation before being cleared by the body. The team's findings, published in Nature Communications, offer a detailed view into the dynamics of metastasis and lay the groundwork for analyzing drug response in real time. This work was supported in part by the Ludwig Center at MIT.

Forest vs. Fires

MIT News

September 22, 2021

Signaling expert Forest White has begun applying his signature analytical techniques to investigate how environmental factors affect cancer development and progression. A recent modeling study challenges current thinking about carcinogenic compounds called polycyclic aromatic hydrocarbons (PAHs), which are released whenever organic matter is burned, including in wildfires, driving, and cooking. The MIT team’s findings, published in GeoHealth, suggest that the PAH historically used to inform regulatory standards may be inadequate for assessing global cancer risk.

Congratulations, Sachin!

MIT News

September 17, 2021

Cheers to graduate student Sachin Bhagchandani, the first at MIT to win the National Cancer Institute Predoctoral to Postdoctoral Fellow Transition Award (F99/K00)! Collaborating with the Johnson, Irvine, Langer, and Spranger Labs, Bhagchandani combines immunology and polymer chemistry to develop a drug delivery system that makes certain kinds of cancer immunotherapies less toxic.

Diet, Cancer, and the Microbiome

Cell Stem Cell

September 15, 2021

Over the years, researchers in the laboratory of Ömer Yilmaz have uncovered important clues into the connections between diet and cancer, with recent work focusing on the role of intestinal stem cells on tumor initiation under various dietary conditions. In a study published in Cell Stem Cell, the lab examines the impact of high fat diets on gut microbes and their interactions with both stem cells and immune cells. The findings suggest that such perturbations to the microbiome significantly dampen immune recognition of premalignant intestinal stem cells, leading to increased tumorigenesis.

Copy That

MIT News

September 15, 2021

Griffith Lab researchers have developed a new way to grow tiny replicas of the pancreas. These “organoids,” described in Nature Materials, can be grown from healthy or cancerous cells and could help researchers develop and test potential drugs for pancreatic cancer—one of the most difficult types of cancer to treat.

Lees Named Associate Dean

MIT News

August 17, 2021

KI associate director and Virginia & D.K. Ludwig Professor for Cancer Research Jacqueline Lees has been appointed associate dean in the MIT School of Science. Lees, along with John W. Jarve (1978) Professor in Brain and Cognitive Sciences Rebecca Saxe, will contribute to the school's diversity, equity, and inclusion activities, as well as develop and implement mentoring and other career-development programs to support the community. This work is well aligned with Lees' longstanding leadership at both the Koch Institute and MIT's Department of Biology, and her ongoing commitment to making discovery science research accessible to all.